These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 26916310

  • 1. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
    Schellings MW, Boonen K, Schmitz EM, Jonkers F, van den Heuvel DJ, Besselaar A, Hendriks JG, van de Kerkhof D.
    Thromb Res; 2016 Mar; 139():128-34. PubMed ID: 26916310
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Quantitation of the Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Warfarin in Plasma Using Ultra-Performance Liquid Chromatography with Tandem Mass Spectrometry (UPLC-MS/MS).
    Noguez JH, Ritchie JC.
    Methods Mol Biol; 2016 Mar; 1383():21-7. PubMed ID: 26660170
    [Abstract] [Full Text] [Related]

  • 4. A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma.
    Lagoutte-Renosi J, Le Poupon J, Girard A, Montange D, Davani S.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Nov 15; 1100-1101():43-49. PubMed ID: 30292948
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T, Flieder T, Fox V, Gripp T, Dittrich M, Kuhn J, Alban S, Knabbe C, Birschmann I.
    Eur J Cardiothorac Surg; 2017 Apr 01; 51(4):624-632. PubMed ID: 28043992
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma.
    Baldelli S, Cattaneo D, Pignatelli P, Perrone V, Pastori D, Radice S, Violi F, Clementi E.
    Bioanalysis; 2016 Feb 01; 8(4):275-83. PubMed ID: 26808218
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
    Gouin-Thibault I, Freyburger G, de Maistre E, Susen S, Delavenne X, Golmard JL, Gruel Y, Sié P, GFHT study group on DOAC.
    Thromb Res; 2017 Oct 01; 158():126-133. PubMed ID: 28892657
    [Abstract] [Full Text] [Related]

  • 17. Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants.
    Ebner M, Peter A, Spencer C, Härtig F, Birschmann I, Kuhn J, Wolf M, Winter N, Russo F, Zuern CS, Blumenstock G, Ziemann U, Poli S.
    Stroke; 2015 Oct 01; 46(10):2741-7. PubMed ID: 26272385
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
    Mani H, Herth N, Kasper A, Wendt T, Schuettfort G, Weil Y, Pfeilschifter W, Linnemann B, Herrmann E, Lindhoff-Last E.
    Ther Drug Monit; 2014 Oct 01; 36(5):624-31. PubMed ID: 24577124
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.